Synapse - Works

Results (115372)

Whole genome sequencing comparison of acute myeloid leukemia at presentation and remission predicts patient outcome

Meeting Abstract

Moffitt, A. B.; Alexander, J.; Stepansky, A.; Famulare, C.; Lopez, C. A.; Hakim, N.; Wu, V.; Wang, Z.; Kolitz, J. E.; Chiorazzi, N.; more...
Blood (2022)

Fulltext@MSK | Save

A multi-center phase Ib trial of the histone deactylase inhibitor (HDACi) entinostat in combination with anti-pd1 antibody pembrolizumab in patients with refractory/relapsed myelodysplastic syndromes (RR-MDS) or oligoblastic acute myeloid leukemia (RR-AML) after hypomethylating agent (HMA) failure

Meeting Abstract

Bewersdorf, J. P.; Shallis, R. M.; Sharon, E.; Caldwell, A.; Wei, W.; Yacoub, A.; Madanat, Y. F.; Zeidner, J. F.; Altman, J. K.; Odenike, O.; more...
Blood (2022)

Fulltext@MSK | Save

Quantitative cytogenetic analysis with karyoParser allows for more precise identification of disease biology, clonal evolution, and etiology of relapse in acute myeloid leukemia

Meeting Abstract

Dilip, D.; Derkach, A.; Menghrajani, K.; Goldberg, A. D.; May, H.; Klimek, V. M.; Galera, P. K.; Xiao, W.; Zhang, Y.; Elemento, O.; more...
Blood (2022)

Fulltext@MSK | Save

A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML)

Meeting Abstract

Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
Blood (2022)

Fulltext@MSK | Save

Impact of allelic state on overall survival in TP53-mutant acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS)

Meeting Abstract

Bewersdorf, J. P.; Hasle, V.; Shallis, R. M.; Thompson, E. G.; de Menezes, D. L.; Rose, S.; Boss, I. W.; Halene, S.; Haferlach, T.; Fox, B.; more...
Blood (2022)

Fulltext@MSK | Save

Adolescent and young adults with ALL who complete therapy on DFCI Consortium ALL trials have excellent long-term overall survival

Meeting Abstract

Valtis, Y. K.; Flamand, Y.; Shimony, S.; Place, A. E.; Silverman, L. B.; Vrooman, L. M.; Brunner, A. M.; Sallan, S. E.; Wadleigh, M.; Stone, R. M.; more...
Blood (2022)

Fulltext@MSK | Save

A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes

Meeting Abstract

Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
Blood (2022)

Fulltext@MSK | Save

Umbrella trial in myeloid malignancies: The myelomatch national clinical trials network precision medicine initiative

Meeting Abstract

Little, R. F.; Othus, M.; Assouline, S.; Ansher, S.; Atallah, E. L.; Lindsley, R. C.; Freidlin, B.; Gore, S. D.; Harris, L.; Hourigan, C. S.; more...
Blood (2022)

Fulltext@MSK | Save

The AP-1/ETS transcription factor network regulates stem cell quiescence and chemotherapy resistance in acute myeloid leukemia

Meeting Abstract

Takao, S.; Morell, V.; Brown, F. C.; Koche, R.; Kentsis, A.
Blood (2022)

Fulltext@MSK | Save

A timelapse of patient and provider care perceptions and educational needs for CLL over three years of tailored educational interventions

Meeting Abstract

Ackbarali, T.; O'Brien, S.; Mato, A. R.; Davids, M. S.
Blood (2022)

Fulltext@MSK | Save